```
 is in DialUnits
? b 410
       19jan03 11:58:06 User208760 Session D2248.1
            $0.26    0.074 DialUnits File1
     $0.26  Estimated cost File1
     $0.26  Estimated cost this search
     $0.26  Estimated total session cost   0.074 DialUnits

File 410:Chronolog(R)  1981-2002/Nov
       (c) 2002 The Dialog Corporation

      Set  Items  Description
      ---  -----  -----------
? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,73,155,399
       19jan03 11:58:12 User208760 Session D2248.2
            $0.00    0.070 DialUnits File410
     $0.00  Estimated cost File410
     $0.01  TELNET
     $0.01  Estimated cost this search
     $0.27  Estimated total session cost   0.144 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R)  1969-2003/Jan W2
         (c) 2003 BIOSIS
*File   5: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File  73:EMBASE  1974-2003/Jan W2
         (c) 2003 Elsevier Science B.V.
*File  73: Alert feature enhanced for multiple files, duplicates
removal, customized scheduling. See HELP ALERT.
  File 155:MEDLINE(R)  1966-2003/Jan W1
*File 155: Updating of completed records has resumed.See Help News155.
Alert feature enhanced with customized scheduling. See HELP ALERT.
  File 399:CA SEARCH(R)  1967-2003/UD=13803
         (c) 2003 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.

      Set  Items  Description
      ---  -----  -----------
? s (laci or lipoprotein(w)associated(w)coagulation(w)inhibitor?)
           3298  LACI
         236527  LIPOPROTEIN
        2589235  ASSOCIATED
         204768  COAGULATION
        2059069  INHIBITOR?
            763  LIPOPROTEIN(W)ASSOCIATED(W)COAGULATION(W)INHIBITOR?
      S1   3948  (LACI OR
                 LIPOPROTEIN(W)ASSOCIATED(W)COAGULATION(W)INHIBITOR?)
? s s1 and (coagulat? or procoagulat? or thrombo?)
           3948  S1
         214782  COAGULAT?
            425  PROCOAGULAT?
         589610  THROMBO?
      S2    988  S1 AND (COAGULAT? OR PROCOAGULAT? OR THROMBO?)
? s s2 and py<1989
Processing
            988  S2
       25130270  PY<1989
      S3     22  S2 AND PY<1989
? rd s3
```

...completed examining records
S4 11 RD S3 (unique items)
? t s4/7/all

4/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

06602335 BIOSIS NO.: 000087044497
PLATELETS SECRETE A **COAGULATION** INHIBITOR FUNCTIONALLY AND ANTIGENICALLY SIMILAR TO THE **LIPOPROTEIN ASSOCIATED COAGULATION INHIBITOR**
AUTHOR: NOVOTNY W F; GIRARD T J; MILETICH J P; BROZE G J JR
AUTHOR ADDRESS: JEWISH HOSPITAL/HEMATOL. RES., 216 S KINGSHIGHWAY, ST. LOUIS, MO 63110.
JOURNAL: BLOOD 72 (6). 1988. 2020-2025. **1988**
FULL JOURNAL NAME: Blood
CODEN: BLOOA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Stimulation with thrombin or the calcium ionophore, A23187 caused human platelets to release a **coagulation** inhibitor similar to the **Lipoprotein Associated Coagulation Inhibitor** (LACl). This was documented functionally, with clotting assays measuring tissue factor inhibition and factor Xa inhibition, as well as immunologically, in a competitive immunoassay. The total amount of LACl released by 3 .times. 108 plateletes after two hours stimulation was 7% to 8% of the amount found in 1 mL of serum. Half of the LACl was released by five minutes. The LACl was present in the platelet supernatant and was not associated with the platelet membrane or shed vesicles. The tissue factor and factor Xa inhibitory activities that were released were neutralized by preincubating the platelet supernatants with specific rabbit polyclonal anti-LACl IgG. On Western blot, platelet LACl appeared to run as a doublet with a molecular weight (mol wt) 45,000 to 47,000. Blood samples obtained from the site of a wound (template bleeding time) demonstrated a progressive increase in LACl concentration. A cDNA probe, derived from endothelial cell LACl cDNA, hybridized selectively to 4.0 and 1.4 kb transcripts in a preparation of platelet mRNA.

4/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

06371683 BIOSIS NO.: 000036074836
HUMAN FIBROBLAST TISSUE FACTOR IS INHIBITED BY **LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR** AND PLACENTAL ANTICOAGULANT PROTEIN BUT NOT BY APOLIPOPROTEIN A-II
AUTHOR: GRAMZINSKI R A; NOVOTNY W F; BROZE G J JR; CARSON S D
AUTHOR ADDRESS: UNIV. COLO. SCH. MED., DENVER, COLO.
JOURNAL: 8TH NATIONAL CONFERENCE ON THROMBOSIS AND HEMOSTASIS, WASHINGTON, D.C., USA, NOVEMBER 1988. ARTERIOSCLEROSIS 8 (5). 1988. 680A. **1988**
CODEN: ARTRD
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

4/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

06180909 BIOSIS NO.: 000086015091

CLONING AND CHARACTERIZATION OF A COMPLEMENTARY DNA CODING FOR THE **LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR** SHOWS THAT IT CONSISTS OF THREE TANDEM KUNITZ-TYPE INHIBITORY DOMAINS
AUTHOR: WUN T-C; KRETZMER K K; GIRARD T J; MILETICH J P; BROZE G J JR
AUTHOR ADDRESS: MONSANTO CO., CHESTERFIELD, MO. 63198.
JOURNAL: J BIOL CHEM 263 (13). 1988. 6001-6004. **1988**
FULL JOURNAL NAME: Journal of Biological Chemistry
CODEN: JBCHA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Human plasma contains a **lipoprotein-associated coagulation inhibitor** (**LACI**) which inactivates factor Xa directly, and in a Xa-dependent fashion also inhibits the VIIa-tissue factor complex of the extrinsic **coagulation** pathway. Rabbit polyclonal anti-**LACI** antiserum was used to screen human placental and fetal liver .lambda.gt11 cDNA libraries for the expression of **LACI** antigens. Immunologically positive clones were further tested for their ability to bind 125I-factor Xa. Seven clones were obtained which are immunologically and functionally active. The longest cDNA insert (.lambda.P9) of these isolates is 1.4 kilobases (kb) while other clones are 1.0 kb in length. Nucleotide sequence analysis shows that .lambda.P9 consists of 1431 bases that include a 5'-noncoding sequence of 132 nucleotides, an open reading frame of 912 nucleotides, and a 3'-noncoding region of 387 nucleotides. The open reading frame encodes a signal peptide of 28 residues followed by a 32-kilodalton protein of 276 residues. The predicted sequence of mature **LACI** contains 18 cysteines and three potential N-linked glycosylation sites. The amino acid sequence analysis of purified **LACI**'s NH2 terminus and two of its proteolytic fragments match exactly those deduced from the cDNA sequence, indicating that the cDNA codes for **LACI**. The translated amino acid sequence of **LACI** shows several discernible domains, including a highly negatively charged NH2 terminus, three tandem Kunitz-type inhibitory domains, and a highly positively charged carboxyl terminus. Northern blot analysis shows that the following liver-derived cell lines, Chang liver, HepG2 hepatoma, and SK hepatoma all, contain two major species of mRNA (1.4 and 4.4 kb) which hybridize with **LACI** cDNA.

4/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

06144568 BIOSIS NO.: 000085107720
THE **LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR** THAT INHIBITS THE FACTOR-VII-TISSUE FACTOR COMPLEX ALSO INHIBITS FACTOR XA INSIGHT INTO ITS POSSIBLE MECHANISM OF ACTION
AUTHOR: BROZE G J JR; WARREN L A; NOVOTNY W F; HIGUCHI D A; GIRARD J J; MILETICH J P
AUTHOR ADDRESS: JEWISH HOSP., 216 S. KINGSHIGHWAY, ST. LOUIS, MO. 63110.
JOURNAL: BLOOD 71 (2). 1988. 335-343. **1988**
FULL JOURNAL NAME: Blood
CODEN: BLOOA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Blood **coagulation** is initiated when plasma factor VII(a) binds to its essential cofactor tissue factor (TF) and proteolytically activates factors X and IX. Progressive inhibition of TF activity occurs upon its addition to plasma. This process is reversible and requires the presence of VII(a), catalytically active Xa, Ca2+, and another component that appears to be associated with the lipoproteins in plasma, a **lipoprotein-associated coagulation inhibitor** (

LACI). A protein, **LACI**(HG2), possessing the same inhibitory properties as **LACI**, has recently been isolated from the conditioned media of cultured human liver cells (HepG2). Rabbit antisera raised against a synthetic peptide based on the N-terminal sequence of **LACI**(HG2) and purified IgG from a rabbit immunized with intact **LACI**(HG2) inhibit the **LACI** activity in human serum. In a reaction mixture containing VII, Xa, Ca2+, and purified **LACI**(HG2), the apparent half-life (t1/2) for TF activity was 20 seconds. The presence of heparin accelerated the initial rate of inhibition threefold. Antithrombin III.alpha. alone had no effect, but antithrombin III.alpha. with heparin abrogated the TF inhibition. **LACI**(HG2) also inhibited Xa with an apparent t1/2 of 50 seconds. Heparin enhanced the rate of Xa inhibition 2.5-fold, whereas phospholipids and Ca2+ slowed the reaction 2.5-fold. Xa inhibition was demonstrable with both chromogenic substrate (S-222) and bioassays, but no complex between Xa and LAC(HG2) could be visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Nondenaturing PAGE, however, showed that **LACI**(HG2) bound to Xa but not to X or Xa inactivated by diisopropyl fluorophosphate. Thus, **LACI**(HG2) appears to bind to Xa at or near its active site. Bovine factor Xa lacking its .gamma.-carboxyglutamic acid-containing domain, BXa(-GD), through treatment with .alpha.-chymotrypsin, was used to further investigate the Xa requirement for VIIa/TF inhibition by **LACI**(HG2). **LACI**(HG2) bound to BXa(-GD) and inhibited its catalytic activity against a small molecular substrate (Spectrozyme Xa), though at a rate approximately sevenfold slower than native BXa. Preincubation of **LACI**(HG2) with saturating concentrations of BXa(-GD) markedly retarded the subsequent inhibition of BXa. The VII(a)/TF complex was not inhibited by **LACI**(HG2) in the presence of BXa(-GD), and further, preincubation of **LACI**(HG2) with BXa(-GD) slowed the inhibition of VIIa/TF after the addition of native Xa. The results are consistent with the hypothesis that inhibition of VII(a)/TF involves the formation of a VIIa-TF-Xa-**LACI** complex that requires the GD of Xa. Because the GD contains the .alpha.-carboxyglutamic acids required for the Ca2+-dependent binding of factor Xa to phospholipid surfaces, the results also suggest that Ca2+ may be required for the native Xa-**LACI** complex to bind to and inhibit VII(A)/TF. **LACI** is a novel inhibitor that can rapidly affect feedback inhibition of the VIIa-Ca2+-TF enzymatic complex after the generation of small amounts of Xa and probably plays an important role in the regulation of in vivo **coagulation**.

4/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

05968744 BIOSIS NO.: 000035060107
PLATELETS RELEASE THE **LIPOPROTEIN ASSOCIATED COAGULATION INHIBITOR** UPON STIMULATION WITH THROMBIN OR A-23187
AUTHOR: NOVOTNY W F; MILETICH J P; BROZE G J JR
AUTHOR ADDRESS: JEWISH HOSP. AT WASHINGTON UNIV. MED. CENT., ST. LOUIS, MO.
JOURNAL: EIGHTIETH ANNUAL NATIONAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, WASHINGTON, D.C., USA, APRIL 29-MAY 2, 1988. CLIN RES 36 (3). 1988. 568A. **1988**
CODEN: CLREA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

4/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

05968728 BIOSIS NO.: 000035060091
CLONING AND SEQUENCING OF A COMPLEMENTARY DNA FOR THE HUMAN **LIPOPROTEIN ASSOCIATED COAGULATION INHIBITOR**
AUTHOR: GIRARD T J; WARREN L A; NOVOTNY W F; MILETICH J P; BROZE G J JR
AUTHOR ADDRESS: JEWISH HOSP. AT WASHININGTON UNIV. MED. CENT., ST. LOUIS, MO.
JOURNAL: EIGHTIETH ANNUAL NATIONAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, WASHINGTON, D.C., USA, APRIL 29-MAY 2, 1988. CLIN RES 36 (3). 1988. 565A. **1988**
CODEN: CLREA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

4/7/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

05789432 BIOSIS NO.: 000034012581
ISOLATION OF THE **LIPOPROTEIN ASSOCIATED COAGULATION INHIBITOR** PRODUCED BY HEPG2 HUMAN HEPATOMA CELLS USING BOVINE FACTOR XA AFFINITY CHROMATOGRAPHY
AUTHOR: BROZE G J JR; WARREN L A; GIRARD J J; MILETICH J P
AUTHOR ADDRESS: DIV. HEMATOL./ONCOL., WASHINGTON UNIV. SCH. MED., JEWISH HOSP., ST. LOUIS, MO., USA.
JOURNAL: THROMB RES 48 (2). 1987. 253-260. **1987**
FULL JOURNAL NAME: Thrombosis Research
CODEN: THBRA
RECORD TYPE: Citation
LANGUAGE: ENGLISH

4/7/8 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE

03794434 EMBASE No: 1988243874
Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli
Amann E.; Ochs B.; Abel K.-J.
Molecular Biology Department, Behringwerke AG, D-3550 Marburg Germany
Gene (GENE) (Netherlands) 1988, 69/2 (301-315)
CODEN: GENED ISSN: 0378-1119
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

A series of new plasmid expression vectors (the pTrc series) has been constructed for the regulated expression of genes in Escherichia coli. Based on pKK233-2 (Amann and Brosius, Gene 40 (1985) 183-190), the vectors carry a strong hybrid trp/lac promoter, the lacZ ribosome-binding site (RBS), the multiple cloning site of pUC18 and the rnnB transcription terminators. With the aid of synthetic oligodeoxynucleotides, the multiple cloning site has been inserted behind an NcoI site in three reading frames. Thus, the vectors are equally useful for the expression of proteins in their authentic, non-fused form (by using the NcoI site) and for the expression of fusion proteins (by choosing any of the cloning sites in the correct translational frame). To ensure complete repression of the hybrid trp/lac promoter during construction and growth in any host strain, the **lacI**(q) allele of the lac repressor gene was added to some of the vectors. The complete vector nucleotide sequence and examples of heterologous gene expression (human **coagulation** factor XIIIa and human placental anticoagulant protein PP4) with the new vectors are presented.

4/7/9 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE

03640083 EMBASE No: 1988089519

The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action

Broze Jr. G.J.; Warren L.A.; Novotny W.F.; Higuchi D.A.; Girard J.J.; Miletich J.P.
Jewish Hospital, St Louis, MO 63110 United States

Blood (BLOOD) (United States) 1988, 71/2 (335-343)
CODEN: BLOOA ISSN: 0006-4971
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Blood **coagulation** is initiated when plasma factor VII(a) binds to its essential cofactor tissue factor (TF) and proteolytically activates factors X and IX. Progressive inhibition of TF activity occurs upon its addition to plasma. This process is reversible and requires the presence of VII(a), catalytically active Xa, Casup 2sup +, and another component that appears to be associated with the lipoproteins in plasma, a **lipoprotein-associated coagulation inhibitor** (**LACI**). A protein, **LACI**(HG2), possessing the same inhibitory properties as **LACI**, has recently been isolated from the conditioned media of cultured human liver cells (HepG2). Rabbit antisera raised against a synthetic peptide based on the N-terminal sequence of **LACI**(HG2) and purified IgG from a rabbit immunized with intact **LACI**(HG2) inhibit the **LACI** activity in human serum. In a reaction mixture containing VIIa, Xa, Casup 2sup +, and purified **LACI**(HG2), the apparent half-life (t1/2) for TF activity was 20 seconds. The presence of heparin accelerated the initial rate of inhibition threefold. Antithrombin IIIalpha alone had no effect, but antithrombin IIIalpha with heparin abrogated the TF inhibition. **LACI**(HG2) also inhibited Xa with an apparent t1/2 of 50 seconds. Heparin enhanced the rate of Xa inhibition 2.5-fold, whereas phospholipids and Casup 2sup + slowed the reaction 2.5-fold. Xa inhibition was demonstrable with both chromogenic substrate (S-2222) and bioassays, but no complex between Xa and **LACI**(HG2) could be visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Nondenaturing PAGE, however, showed that **LACI**(HG2) bound to Xa but not to X or Xa inactivated by diisopropyl fluorophosphate. Thus, **LACI** (HG2) appears to bind to Xa at or near its active site. Bovine factor Xa lacking its gamma-carboxyglutamic acid-containing domain, BXa(-GD), through treatment with alpha-chymotrypsin, was used to further investigate the Xa requirement for VIIa/TF inhibition by **LACI**(HG2). **LACI**(HG2) bound to BXa(-GD) and inhibited its catalytic activity against a small molecular substrate (Spectrozyme Xa), though at a rate approximately sevenfold slower than native BXa. Preincubation of **LACI**(HG2) with saturating concentrations of BXa(-GD) markedly retarded the subsequent inhibition of BXa. The VII(a)/TF complex was not inhibited by **LACI** (HG2) in the presence of BXa(-GD), and further, preincubation of **LACI** (HG2) with BXa(-GD) slowed the inhibition of VIIa/TF after the addition of native Xa. The results are consistent with the hypothesis that inhibiton of VII(a)/TF involves the formation of a VIIa-TF-Xa-**LACI** complex that requires the GD of Xa. Because the GD contains the alpha-carboxyglutamic acids required for the Casup 2sup +-dependent binding of factor Xa to phospholipid surfaces, the results also suggest that Casup 2sup + may be required for the native Xa-**LACI** complex to bind to and inhibit VII(a)/TF. **LACI** is a novel inhibitor that can rapidly affect feedback inhibition of the VIIa-Casup 2sup +-TF enzymatic complex after the generation of small amounts of Xa and probably plays an important role in the regulation of the in vivo **coagulation**.

4/7/10 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

06098420 89187705 PMID: 3238648
Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition.
Warn-Cramer B J; Rao L V; Maki S L; Rapaport S I
Department of Medicine, University of California, San Diego, La Jolla 92103.
Thrombosis and haemostasis (GERMANY, WEST) Dec 22 **1988**, 60 (3) p453-6, ISSN 0340-6245 Journal Code: 7608063
Contract/Grant No.: H L27234; .PHS
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Inhibition of factor VIIa/tissue factor (TF) by extrinsic pathway inhibitor (EPI) requires the participation of factor Xa. Through this inhibition, factor Xa generated initially may feed back to suppress continuing generation of factor Xa via the extrinsic pathway during hemostasis. We have utilized chemical modifications of EPI and factor Xa to study the reactions responsible for inhibition. The data are consistent with a two-step model. First, EPI binds to factor Xa in a Ca2+ independent reaction in which the gla-domain of factor Xa does not participate. A functional active site on factor Xa and arginine residues on EPI are essential for this step. Then the factor Xa/EPI complex binds to factor VIIa/TF with resultant inhibition of its enzymatic activity. The gla-domain of factor Xa is essential for this step. Intact positively charged lysines on factor Xa may also be important.
Record Date Created: 19890501

4/7/11 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

05430087 87175579 PMID: 3031657
Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells.
Broze G J; Miletich J P
Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Apr **1987**, 84 (7) p1886-90, ISSN 0027-8424 Journal Code: 7505876
Contract/Grant No.: HL34462; HL; NHLBI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Progressive inhibition of tissue factor activity occurs upon its addition to human plasma (serum). This process requires the presence of factor VII(a), facto-X(a), Ca2+, and another component in plasma that we have called the tissue factor inhibitor (TFI). A TFI secreted by HepG2 cells (human hepatoma cell line) was isolated from serum-free conditioned medium in a four-step procedure including CdCl2 precipitation, diisopropylphosphoryl-factor Xa affinity chromatography, Sephadex G-75 superfine gel filtration, and Mono Q ion-exchange chromatography. The purified TFI contained a predominant band at Mr 38,000 on NaDodSO4/polyacrylamide gel electrophoresis that comigrates with inhibitory activity. Like the activity present in plasma, this TFI requires the presence of factor VII(a), factor X(a), and Ca2+ to express inhibitory activity. Its specific activity (assuming an extinction coefficient of 10 at 280 nM, for a 1-cm path length through a 1% solution) was 9800 units/mg

of protein, where 1 unit of TFI activity was defined as that present in 1 ml of normal pooled serum.

Record Date Created: 19870504

?

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
LACI.DWPI,EPAB,JPAB,USPT,PGPB.	1859
LACIS.DWPI,EPAB,JPAB,USPT,PGPB.	29
LIPOPROTEIN.DWPI,EPAB,JPAB,USPT,PGPB.	11067
LIPOPROTEINS.DWPI,EPAB,JPAB,USPT,PGPB.	6532
ASSOCIATED.DWPI,EPAB,JPAB,USPT,PGPB.	1540838
ASSOCIATEDS.DWPI,EPAB,JPAB,USPT,PGPB.	6
COAGULATION.DWPI,EPAB,JPAB,USPT,PGPB.	54579
COAGULATIONS.DWPI,EPAB,JPAB,USPT,PGPB.	305
FACTOR.DWPI,EPAB,JPAB,USPT,PGPB.	564049
FACTORS.DWPI,EPAB,JPAB,USPT,PGPB.	414509
COAGULATION.USPT,PGPB.	31785
((LACI OR LIPOPROTEIN ADJ ASSOCIATED ADJ COAGULATION ADJ FACTOR) SAME (COAGULATION OR COAGULANT OR PROCOAGULAT$ OR THROMBO$).CLM.).USPT,PGPB,JPAB,EPAB,DWPI.	5

There are more results than shown above. Click here to view the entire set.

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L4

Refine Search

Recall Text | Clear

Search History

DATE: Sunday, January 19, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L4	(laci or lipoprotein adj associated adj coagulation adj factor) same (coagulation or coagulant or procoagulat$ or thrombo$).clm.	5	L4
L3	(laci or lipoprotein adj associated adj coagulation adj factor) same (coagulation or coagulant or procoagulat$)	122	L3
DB=USPT; PLUR=YES; OP=ADJ			
L2	(laci or lipoprotein adj associated adj coagulation adj factor)	1274	L2
DB=USPT,PGPB; PLUR=YES; OP=ADJ			
L1	(laci or lipoprotein adj associated adj coagulation adj factor)	1820	L1

END OF SEARCH HISTORY

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
LACI.DWPI,EPAB,JPAB,USPT,PGPB.	1859
LACIS.DWPI,EPAB,JPAB,USPT,PGPB.	29
LIPOPROTEIN.DWPI,EPAB,JPAB,USPT,PGPB.	11067
LIPOPROTEINS.DWPI,EPAB,JPAB,USPT,PGPB.	6532
ASSOCIATED.DWPI,EPAB,JPAB,USPT,PGPB.	1540838
ASSOCIATEDS.DWPI,EPAB,JPAB,USPT,PGPB.	6
COAGULATION.DWPI,EPAB,JPAB,USPT,PGPB.	54579
COAGULATIONS.DWPI,EPAB,JPAB,USPT,PGPB.	305
FACTOR.DWPI,EPAB,JPAB,USPT,PGPB.	564049
FACTORS.DWPI,EPAB,JPAB,USPT,PGPB.	414509
COAGULANT.DWPI,EPAB,JPAB,USPT,PGPB.	15271
((LACI OR LIPOPROTEIN ADJ ASSOCIATED ADJ COAGULATION ADJ FACTOR) SAME (COAGULATION OR COAGULANT OR PROCOAGULAT$)).USPT,PGPB,JPAB,EPAB,DWPI.	122

There are more results than shown above. Click here to view the entire set.

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L3

Refine Search

Recall Text | Clear

Search History

DATE: Sunday, January 19, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L3	(laci or lipoprotein adj associated adj coagulation adj factor) same (coagulation or coagulant or procoagulat$)	122	L3
DB=USPT; PLUR=YES; OP=ADJ			
L2	(laci or lipoprotein adj associated adj coagulation adj factor)	1274	L2
DB=USPT,PGPB; PLUR=YES; OP=ADJ			
L1	(laci or lipoprotein adj associated adj coagulation adj factor)	1820	L1

END OF SEARCH HISTORY

WEST

Generate Collection Print

L4: Entry 2 of 5 File: USPT Sep 18, 2001

US-PAT-NO: 6291427
DOCUMENT-IDENTIFIER: US 6291427 B1

TITLE: Anticoagulant combination of LACI and sulfated polysaccharides

DATE-ISSUED: September 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wun; Tze-Chein	St. Louis	MO		

US-CL-CURRENT: 514/12; 514/21, 530/395

CLAIMS:

What is claimed is:

1. A composition essentially free from antithrombin and consisting essentially of LACI and an anticoagulant sulfated polysaccharide in proportions that provide a synergistic anticoagulation effect upon administration to a warm-blooded mammal.

2. A composition of claim 1 in which the sulfated polysaccharide is selected from the group consisting of heparin, pentosan sulfate, dermatan sulfate, dextran sulfate and heparan sulfate.

3. A composition according to claim 1 in which heparin and LACI are in proportions of from about 0.1 to about 4 units of said heparin and from about 0.1 to about 5 .mu.g of LACI.

4. A method of inhibiting blood coagulation in whole blood plasma of a warm blooded mammal comprising exogenously administering to said mammal an effective synergistic anticoagulant amount of an anticoagulant sulfated polysaccharide and LACI essentially free from antithrombin.

5. The method of claim 4 in which the sulfated polysaccharide is selected from the group consisting of heparin, pentosan sulfate, dermatan sulfate, dextran sulfate and heparan sulfate.

6. The method of claim 4 in which the administration is parenterally in an amount of from 0.1 to about 4 units of heparin and from about 0.1 to about 5 .mu.g of LACI per ml of plasma treated.

WEST

Generate Collection Print

L4: Entry 2 of 5 File: USPT Sep 18, 2001

DOCUMENT-IDENTIFIER: US 6291427 B1
TITLE: Anticoagulant combination of LACI and sulfated polysaccharides

CLAIMS:

4. A method of inhibiting blood coagulation in whole blood plasma of a warm blooded mammal comprising exogenously administering to said mammal an effective synergistic anticoagulant amount of an anticoagulant sulfated polysaccharide and LACI essentially free from antithrombin.

WEST

End of Result Set

☑ Generate Collection | Print

L4: Entry 5 of 5 File: USPT Apr 21, 1992

US-PAT-NO: 5106833
DOCUMENT-IDENTIFIER: US 5106833 A

TITLE: Coagulation inhibitors

DATE-ISSUED: April 21, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Broze, Jr.; George J.	St. Louis	MO		
Girard; Thomas J.	St. Louis	MO		

US-CL-CURRENT: 514/12; 424/529, 530/300, 530/350

CLAIMS:

What is claimed is:

1. A novel blood coagulation inhibitor selected from the group consisting of

(A) a peptide fragment of lipoprotein-associated coagulation inhibitor having the sequence of residues 90 to 160 of the 276 residue mature LACI protein, and

(B) a peptide fragment of lipoprotein-associated coagulation inhibitor having the sequence of residues 19 to 160 or 1 to 160 of the 276 residue mature LACI protein.

2. A method of inhibiting Factor Xa production in a mammal comprising administering to said mammal an effective amount of a peptide fragment of lipoprotein-associated coagulation inhibitor having the sequence of residues 90 to 160 of the 276 residue mature LACI protein.

3. A method of inhibiting Factor VIIa/TF enzymatic complex formation in a mammal comprising administering to said mammal an effective amount of a peptide fragment of lipoprotein-associated coagulation inhibitor having the sequence of residues 19 to 160 or 1 to 160 of the 276 residue mature LACI protein.

WEST

Generate Collection | Print

Search Results - Record(s) 1 through 5 of 5 returned.

☐ 1. Document ID: US 20020192675 A1

L4: Entry 1 of 5 File: PGPB Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020192675
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020192675 A1

TITLE: Methods of identifying regulator molecules

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zauderer, Maurice	Pittsford	NY	US	
Smith, Ernest S.	Ontario	NY	US	

US-CL-CURRENT: 435/6; 435/455, 435/7.1, 435/7.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 2. Document ID: US 6291427 B1

L4: Entry 2 of 5 File: USPT Sep 18, 2001

US-PAT-NO: 6291427
DOCUMENT-IDENTIFIER: US 6291427 B1

TITLE: Anticoagulant combination of LACI and sulfated polysaccharides

DATE-ISSUED: September 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wun; Tze-Chein	St. Louis	MO		

US-CL-CURRENT: 514/12; 514/21, 530/395

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 3. Document ID: US 6071723 A

L4: Entry 3 of 5 File: USPT Jun 6, 2000

US-PAT-NO: 6071723
DOCUMENT-IDENTIFIER: US 6071723 A

TITLE: Inhibitors of human plasmin derived from the Kunitz domains

DATE-ISSUED: June 6, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Markland; William	Milford	MA		
Ladner; Robert Charles	Ijamsville	MD		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/69.2, 530/300, 530/324, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 5369038 A

L4: Entry 4 of 5 File: USPT Nov 29, 1994

US-PAT-NO: 5369038
DOCUMENT-IDENTIFIER: US 5369038 A

TITLE: Method for immunological assay of free lipoprotein associated coagulation inhibitor (LACI) and kit therefor

DATE-ISSUED: November 29, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Koike; Yukiya	Hino			JP
Suzuki; Koji	Tsu			JP
Ichikawa; Yataro	Tokorozawa			JP

US-CL-CURRENT: 436/548; 435/7.1, 435/7.94, 435/975, 530/388.25

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 5106833 A

L4: Entry 5 of 5 File: USPT Apr 21, 1992

US-PAT-NO: 5106833
DOCUMENT-IDENTIFIER: US 5106833 A

TITLE: Coagulation inhibitors

DATE-ISSUED: April 21, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Broze, Jr.; George J.	St. Louis	MO		
Girard; Thomas J.	St. Louis	MO		

US-CL-CURRENT: 514/12; 424/529, 530/300, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | KWIC | Draw Desc | Image

---

Generate Collection | Print

Term	Documents
LACI.DWPI,EPAB,JPAB,USPT,PGPB.	1859
LACIS.DWPI,EPAB,JPAB,USPT,PGPB.	29
LIPOPROTEIN.DWPI,EPAB,JPAB,USPT,PGPB.	11067
LIPOPROTEINS.DWPI,EPAB,JPAB,USPT,PGPB.	6532
ASSOCIATED.DWPI,EPAB,JPAB,USPT,PGPB.	1540838
ASSOCIATEDS.DWPI,EPAB,JPAB,USPT,PGPB.	6
COAGULATION.DWPI,EPAB,JPAB,USPT,PGPB.	54579
COAGULATIONS.DWPI,EPAB,JPAB,USPT,PGPB.	305
FACTOR.DWPI,EPAB,JPAB,USPT,PGPB.	564049
FACTORS.DWPI,EPAB,JPAB,USPT,PGPB.	414509
COAGULATION.USPT,PGPB.	31785
((LACI OR LIPOPROTEIN ADJ ASSOCIATED ADJ COAGULATION ADJ FACTOR) SAME (COAGULATION OR COAGULANT OR PROCOAGULAT$ OR THROMBO$).CLM.).USPT,PGPB,JPAB,EPAB,DWPI.	5

There are more results than shown above. Click here to view the entire set.

Display Format: - Change Format

Previous Page Next Page